Claritev Corporation logo

Claritev Corporation

CTEV

NYSEHealthcareMedical - Healthcare Information Services

Regular session

$37.85

+$0.58 · +1.56%

Aug 24, 10:39 AM ETData delayed

CTEV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

100

Deep Value

Momentum

42

Neutral

Sentiment

56

Mixed

Risk resilience

34

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Travis S. Dalton
Listed since
Apr 3, 2020
Employees
3,000

Market position

Day range

Current $37.85

52-week range

Current $37.85

Open
$37.53
Previous close
$37.27
Volume
11.38K
0.08× average
Average volume
138.77K
Average daily volume
Market cap
645.26M USD
Beta
0.79
Market reference 1
50-day average
$30.4882
+24.15% above average
200-day average
$29.1309
+29.93% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
5.32B USD
EV / EBITDA
11.19×
Earnings yield
-40.46%
Free cash flow yield
-1.75%

Profitability & efficiency

Return on equity
163.47%
Return on assets
-5.82%
Return on invested capital
0.74%

Financial health

Current ratio
0.86×
Altman Z-score
-0.42
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends110%6%-99%-203%Gross margin, FY2021: 84.32%Gross margin, FY2022: 81.10%Gross margin, FY2023: 75.51%Gross margin, FY2024: 74.27%Gross margin, FY2025: 27.61%Operating margin, FY2021: 34.55%Operating margin, FY2022: -33.60%Operating margin, FY2023: 16.85%Operating margin, FY2024: -149.35%Operating margin, FY2025: 4.67%Net margin, FY2021: 9.13%Net margin, FY2022: -53.06%Net margin, FY2023: -9.54%Net margin, FY2024: -176.85%Net margin, FY2025: -29.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 84.32%. Gross margin FY2022 81.10%. Gross margin FY2023 75.51%. Gross margin FY2024 74.27%. Gross margin FY2025 27.61%. Operating margin FY2021 34.55%. Operating margin FY2022 -33.60%. Operating margin FY2023 16.85%. Operating margin FY2024 -149.35%. Operating margin FY2025 4.67%. Net margin FY2021 9.13%. Net margin FY2022 -53.06%. Net margin FY2023 -9.54%. Net margin FY2024 -176.85%. Net margin FY2025 -29.45%.

Income trends

Revenue

965.41M USD+3.74%

Operating income

45.06M USD+1.43B USD

Net income

−284.28M USD+82.73%
Income trends across reported periods1.39B USD288.57M USD−816.8M USD−1.92B USDRevenue, FY2021: 1.12B USDRevenue, FY2022: 1.08B USDRevenue, FY2023: 961.52M USDRevenue, FY2024: 930.62M USDRevenue, FY2025: 965.41M USDOperating income, FY2021: 386.12M USDOperating income, FY2022: −362.73M USDOperating income, FY2023: 161.98M USDOperating income, FY2024: −1.39B USDOperating income, FY2025: 45.06M USDNet income, FY2021: 102.08M USDNet income, FY2022: −572.91M USDNet income, FY2023: −91.7M USDNet income, FY2024: −1.65B USDNet income, FY2025: −284.28M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.12B USD. Revenue FY2022 1.08B USD. Revenue FY2023 961.52M USD. Revenue FY2024 930.62M USD. Revenue FY2025 965.41M USD. Operating income FY2021 386.12M USD. Operating income FY2022 −362.73M USD. Operating income FY2023 161.98M USD. Operating income FY2024 −1.39B USD. Operating income FY2025 45.06M USD. Net income FY2021 102.08M USD. Net income FY2022 −572.91M USD. Net income FY2023 −91.7M USD. Net income FY2024 −1.65B USD. Net income FY2025 −284.28M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue965.41M USD930.62M USD961.52M USD1.08B USD1.12B USD
Cost of goods sold698.84M USD239.4M USD235.47M USD204.1M USD175.29M USD
Gross profit266.58M USD691.22M USD726.06M USD875.62M USD942.31M USD
Selling, general, and administrative221.52M USD160.22M USD135.99M USD132.14M USD151.1M USD
Operating expenses221.52M USD2.08B USD564.07M USD1.24B USD556.19M USD
Interest income1.56M USD3.13M USD8.23M USD3.5M USD30K USD
Interest expense400.07M USD326.37M USD333.21M USD303.4M USD267.48M USD
Depreciation and amortization448.45M USD436.44M USD425.79M USD415.66M USD412.06M USD
Operating income45.06M USD−1.39B USD161.98M USD−362.73M USD386.12M USD
Net income−284.28M USD−1.65B USD−91.7M USD−572.91M USD102.08M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-413.98%
11 comparable reports
Latest EPS result
-3.49
Estimate -4.12 · Beat by 15.29%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.7-2.42-6.54-10.66Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -8.82, estimate -9.81, surprise +10.09%, Beat. Q2 2025, reported May 8, 2025: actual -4.38, estimate -2.2, surprise -99.09%, Miss. Q3 2025, reported Aug 6, 2025: actual -3.81, estimate -2.69, surprise -41.64%, Miss. Q4 2025, reported Nov 7, 2025: actual -4.23, estimate -3.12, surprise -35.58%, Miss. Q1 2026, reported Feb 23, 2026: actual -4.88, estimate 0.85, surprise -674.12%, Miss. Q2 2026, reported May 7, 2026: actual -4.41, estimate -3.81, surprise -15.75%, Miss. Q3 2026, reported Aug 7, 2026: actual -3.49, estimate -4.12, surprise +15.29%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate -3.63, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates267.78M251.52M235.26M218.99MQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 232.1M USD, estimate 234.34M USD, surprise -0.96%, Miss. Q2 2025, reported May 8, 2025: actual 231.33M USD, estimate 229.29M USD, surprise +0.89%, Beat. Q3 2025, reported Aug 6, 2025: actual 241.57M USD, estimate 231.36M USD, surprise +4.41%, Beat. Q4 2025, reported Nov 7, 2025: actual 245.96M USD, estimate 241.02M USD, surprise +2.05%, Beat. Q1 2026, reported Feb 23, 2026: actual 246.55M USD, estimate 241.24M USD, surprise +2.20%, Beat. Q2 2026, reported May 7, 2026: actual 244.68M USD, estimate 242.71M USD, surprise +0.81%, Beat. Q3 2026, reported Aug 7, 2026: actual 257.48M USD, estimate 244.81M USD, surprise +5.17%, Beat. Q4 2026, reported Nov 6, 2026: actual —, estimate 256.46M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$52.00

37.38% upside
Past 12 months12-month forecastHigh $73.00Average $52.00Low $40.00

Corporate actions

Corporate action history

Stock split

Effective Sep 23, 2024

1:40

CTEV peers

ETFs holding CTEV

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research CTEV

research.disclaimer